Madrigal Pharmaceuticals, Inc. (MDGL) financial statements and ratios from SEC XBRL: revenue $1.5B (TTM), net margin -30.1%, revenue growth 432.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $958.40M |
| Revenue (TTM) | $1.5B |
| Net Margin | -30.1% |
| Operating Margin (TTM) | -23.0% |
| Net Debt / EBITDA | -0.1 |
| Revenue Growth (YoY) | 432.1% |
| EPS Growth (YoY) | -41.3% |
| FCF Growth (YoY) | -58.4% |
| Price / Book | 22.80 |
| Price / Sales | 9.37 |
| FCF Yield | -4.6% |
| Altman Z-Score | 9.37 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
MDGL overview · MDGL earnings · MDGL KPIs · MDGL documents · MDGL ownership · MDGL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.